Tetra Radar · FDA Approvals · Decision date
Pixclara: FDA decision date
Telix Pharmaceuticals Ltd (TLX) · 11 September 2026
Delivering against our 2026 strategic priorities 5 Continue commercial growth Secured Prescription Drug User Fee Act date for Pixclara®1, September 11, 20262 Pixlumi®1 Marketing Authorization Application accepted for review in Europe3 Advancing Phase 3 therapeutics programs:.
Source: 6-K of 20 August 2026
The FDA approved it on 11 September 2026.
The FDA approved Pixclara to use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations.
Telix Pharmaceuticals Ltd on Tetra Radar
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.